Clinical Usefulness of a Functional Assay for the von Willebrand Factor Cleaving Protease (ADAMTS 13) and Its Inhibitor in a Patient with Thrombotic Thrombocytopenic Purpura

American Journal of Hematology

Volumn 75, Issue 2, 2004, Pages 96-100

  Rick, Margaret E ^a,c   Austin, H ^b   Leitman, S F ^a   Krizek, D M ^a   Aronson, D L ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

ADAMTS 13 assay; Plasma exchange; TTP; Von Willebrand factor cleaving protease

Indexed keywords

CREATININE; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ABDOMINAL PAIN; ADULT; ANEMIA; ARTICLE; CASE REPORT; CREATININE BLOOD LEVEL; DIAGNOSTIC VALUE; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; FEVER; HEMOLYSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PLASMAPHERESIS; PRIORITY JOURNAL; RETICULOCYTE COUNT; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADAM PROTEINS; ADULT; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; METALLOENDOPEPTIDASES; PLASMA EXCHANGE; PROTEASE INHIBITORS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; TREATMENT OUTCOME; VON WILLEBRAND FACTOR;

EID: 0742305180     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.10457     Document Type: Article

References (24)

1. Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine 1966;45:139-159.
2. George JN. How 1 treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood 2000;96:1223-1229.
3. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor Vlll:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982;307:1432-1435.
4. Furlan M, Robles R, Lamie B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996;87: 4223-4234.
5. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996;87:4235-4244.
6. Chow TW, Turner NA, Chintagumpala M, et al. Increased von Willebrand factor binding to platelets in single episode and recurrent types of thrombotic thrombocytopenic purpura. Am J Hematol 1998;57:293-302.
7. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002;347: 589-600.
8. Gerritsen HE, Robles R, Lämmle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood 2001;98:1654-1661.
9. Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001;98:1662-1666.
10. Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001;276:41059-41063.
11. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001;413:488-494.
12. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998;339:1578-1584.
13. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998;339:1585-1594.
14. Moore JC, Hayward CP, Warkentin TE, Kelton JG. Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. Blood 2001;98:1842-1846.
15. Veyradier A, Obert B, Houllier A, Meyer D, Girma JP. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 2001;98:1765-1772.
16. Rick ME, Moll S, Taylor MA, Krizek DM, White GC II, Aronson DL. Clinical use of a rapid collagen binding assay for von Willebrand factor cleaving protease in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 2002;88:598-604.
17. Eldor A. Thrombotic thrombocytopenic purpura: diagnosis, pathogenesis and modern therapy. Bailliere's Clin Haematol 1998;11:475-495.
18. Mori Y, Wada H, Gabazza EC, et al. Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity. Transfusion 2002;42:572-580.
19. Aronson DL, Krizek DM, Rick ME. A rapid assay for the vWF protease. Thromb Haemost 2001;85:184-185.
20. rd meeting of the American Society of Hematology, 8 December 2001, Orlando, FL. Washington, DC: American Society of Hematology; 2001. Abstract 132.
21. Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001;98:2730-2735.
22. Rizvi MA, Vesely SK, George JN, et al. Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura hemolytic-uremic syndrome. Transfusion 2000;40:896-901.
23. Langer F, Bergmann F, Budde U, Hegewisch-Becker S, Hossfeld DK. Prolonged inhibition of von Willebrand factor-cleaving protease after splenectomy in a 22-year-old patient with acute and plasma refractory thrombotic thrombocytopenic purpura. Br J Haematol 2002;118: 271-274.
24. Zheng X, Pallera AM, Goodnough LT, Sadler JE, Blinder MA. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med 2003;138:105-108.